Join
Live feed
·
INSIDERFilingvia Quantisnow
Enliven Therapeutics Inc. logo

CHIEF FINANCIAL OFFICER Hohl Benjamin sold $352,551 worth of shares (6,018 units at $58.58) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 40,036 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
ELVN· Enliven Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ELVN (Enliven Therapeutics Inc.) and more on Quantisnow.